362 related articles for article (PubMed ID: 22067401)
1. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
Oberholzer PA; Kee D; Dziunycz P; Sucker A; Kamsukom N; Jones R; Roden C; Chalk CJ; Ardlie K; Palescandolo E; Piris A; MacConaill LE; Robert C; Hofbauer GF; McArthur GA; Schadendorf D; Garraway LA
J Clin Oncol; 2012 Jan; 30(3):316-21. PubMed ID: 22067401
[TBL] [Abstract][Full Text] [Related]
2. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Su F; Viros A; Milagre C; Trunzer K; Bollag G; Spleiss O; Reis-Filho JS; Kong X; Koya RC; Flaherty KT; Chapman PB; Kim MJ; Hayward R; Martin M; Yang H; Wang Q; Hilton H; Hang JS; Noe J; Lambros M; Geyer F; Dhomen N; Niculescu-Duvaz I; Zambon A; Niculescu-Duvaz D; Preece N; Robert L; Otte NJ; Mok S; Kee D; Ma Y; Zhang C; Habets G; Burton EA; Wong B; Nguyen H; Kockx M; Andries L; Lestini B; Nolop KB; Lee RJ; Joe AK; Troy JL; Gonzalez R; Hutson TE; Puzanov I; Chmielowski B; Springer CJ; McArthur GA; Sosman JA; Lo RS; Ribas A; Marais R
N Engl J Med; 2012 Jan; 366(3):207-15. PubMed ID: 22256804
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma.
Cammareri P; Rose AM; Vincent DF; Wang J; Nagano A; Libertini S; Ridgway RA; Athineos D; Coates PJ; McHugh A; Pourreyron C; Dayal JH; Larsson J; Weidlich S; Spender LC; Sapkota GP; Purdie KJ; Proby CM; Harwood CA; Leigh IM; Clevers H; Barker N; Karlsson S; Pritchard C; Marais R; Chelala C; South AP; Sansom OJ; Inman GJ
Nat Commun; 2016 Aug; 7():12493. PubMed ID: 27558455
[TBL] [Abstract][Full Text] [Related]
4. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Arnault JP; Mateus C; Escudier B; Tomasic G; Wechsler J; Hollville E; Soria JC; Malka D; Sarasin A; Larcher M; André J; Kamsu-Kom N; Boussemart L; Lacroix L; Spatz A; Eggermont AM; Druillennec S; Vagner S; Eychène A; Dumaz N; Robert C
Clin Cancer Res; 2012 Jan; 18(1):263-72. PubMed ID: 22096025
[TBL] [Abstract][Full Text] [Related]
5. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
6. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
Escuin-Ordinas H; Atefi M; Fu Y; Cass A; Ng C; Huang RR; Yashar S; Comin-Anduix B; Avramis E; Cochran AJ; Marais R; Lo RS; Graeber TG; Herschman HR; Ribas A
Mol Oncol; 2014 Mar; 8(2):250-60. PubMed ID: 24345644
[TBL] [Abstract][Full Text] [Related]
7. [Squamous cell carcinoma in a patient receiving sorafenib].
Adnot-Desanlis L; Bernard P; Reguiaï Z
Ann Dermatol Venereol; 2011 Feb; 138(2):120-3. PubMed ID: 21333823
[TBL] [Abstract][Full Text] [Related]
8. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.
Holderfield M; Lorenzana E; Weisburd B; Lomovasky L; Boussemart L; Lacroix L; Tomasic G; Favre M; Vagner S; Robert C; Ghoddusi M; Daniel D; Pryer N; McCormick F; Stuart D
Cancer Res; 2014 Apr; 74(8):2238-45. PubMed ID: 24523442
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy.
Yin VT; Wiraszka TA; Tetzlaff M; Curry JL; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2015; 31(4):e112-5. PubMed ID: 24833447
[TBL] [Abstract][Full Text] [Related]
11. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
Chu EY; Wanat KA; Miller CJ; Amaravadi RK; Fecher LA; Brose MS; McGettigan S; Giles LR; Schuchter LM; Seykora JT; Rosenbach M
J Am Acad Dermatol; 2012 Dec; 67(6):1265-72. PubMed ID: 22609219
[TBL] [Abstract][Full Text] [Related]
12. Progression of RAS-mutant leukemia during RAF inhibitor treatment.
Callahan MK; Rampal R; Harding JJ; Klimek VM; Chung YR; Merghoub T; Wolchok JD; Solit DB; Rosen N; Abdel-Wahab O; Levine RL; Chapman PB
N Engl J Med; 2012 Dec; 367(24):2316-21. PubMed ID: 23134356
[TBL] [Abstract][Full Text] [Related]
13. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis.
South AP; Purdie KJ; Watt SA; Haldenby S; den Breems N; Dimon M; Arron ST; Kluk MJ; Aster JC; McHugh A; Xue DJ; Dayal JH; Robinson KS; Rizvi SH; Proby CM; Harwood CA; Leigh IM
J Invest Dermatol; 2014 Oct; 134(10):2630-2638. PubMed ID: 24662767
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
15. Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations.
Schrama D; Groesser L; Ugurel S; Hafner C; Pastrana DV; Buck CB; Cerroni L; Theiler A; Becker JC
JAMA Dermatol; 2014 Nov; 150(11):1180-6. PubMed ID: 24943872
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.
Anforth R; Tembe V; Blumetti T; Fernandez-Peñas P
Pigment Cell Melanoma Res; 2012 Sep; 25(5):569-72. PubMed ID: 22726224
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
18. Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.
Dai J; Kunder CA; Chu EY; Chan EF; Egan CL; Novoa RA
J Cutan Pathol; 2017 Dec; 44(12):1053-1056. PubMed ID: 28796396
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
